Progress in emerging therapies for advanced prostate cancer

Cancer Treatment Reviews

Volumn 39, Issue 3, 2013, Pages 275-289

  Oudard, Stéphane ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Androgen deprivation therapy; Bone metastasis; Bone targeted agent; Chemotherapy; Immunotherapy; Metastatic castration resistant prostate cancer; Skeletal related event

Indexed keywords

ABARELIX; ABIRATERONE ACETATE; AFLIBERCEPT; ATRASENTAN; BEVACIZUMAB; CABAZITAXEL; CABOZANTINIB; DASATINIB; DEGARELIX; DENOSUMAB; DOCETAXEL; ENZALUTAMIDE; ESTRAMUSTINE; IPILIMUMAB; LENALIDOMIDE; LEUPRORELIN; PREDNISONE; SATRAPLATIN; SIPULEUCEL T; TASQUINIMOD; ZIBOTENTAN; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL ACTIVATION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EMBOLISM; EUROPEAN UNION; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; HAND FOOT SYNDROME; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; KIDNEY FAILURE; LEUKOPENIA; LIVER FUNCTION; LUNG EMBOLISM; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; REVIEW; RHINITIS; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; UNITED STATES; UNSPECIFIED SIDE EFFECT;

HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84873987024     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.09.005     Document Type: Review

References (124)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer. <> [accessed 11 July 2011]. http://globocan.iarc.fr.
2. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46:765-781.
3. Lepor H. Comparison of single-agent androgen suppression for advanced prostate cancer. Rev Urol 2005, 7(Suppl. 5):S3-S12.
4. Thompson I.M. Flare associated with LHRH-agonist therapy. Rev Urol 2001, 3(Suppl. 3):S10-S14.
5. Boccon-Gibod L., van der Meulen E., Persson B.E. An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. Ther Adv Urol 2011, 3:127-140.
6. US Food and Drug Administration: Drugs@FDA database. Abarelix, physician package insert. <>; 2011 [accessed 5 December 2011]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21320_plenaxis_lbl.pdf.
7. US Food and Drug Administration: Drugs@FDA database. Abarelix, labelling revision. <>; 2011 [accessed 5 December 2011]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021320s002lbl.pdf.
8. Klotz L., Boccon-Gibod L., Shore N.D., Andreou C., Persson B.E., Cantor P., et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008, 102:1531-1538.
9. Crawford E.D., Tombal B., Miller K., Boccon-Gibod L., Schroder F., Shore N., et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol 2011, 186:889-897.
10. European Association of Urology. Guidelines on Prostate Cancer (January 2011 update). <>; 2011 [accessed 21 November 2011]. http://www.uroweb.org/gls/pdf/08_Prostate_Cancer%20September%2022nd%202011.pdf.
11. Tombal B., Miller K., Boccon-Gibod L., Schroder F., Shore N., Crawford E.D., et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol 2010, 57:836-842.
12. Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
13. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
14. Kantoff P.W., Halabi S., Conaway M., Picus J., Kirshner J., Hars V., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol: Official J Am Soc Clin Oncol 1999, 17:2506-2513.
15. Armstrong A.J., George D.J. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostatic Dis 2010, 13:108-116.
16. Ferrer F.A., Miller L.J., Lindquist R., Kowalczyk P., Laudone V.P., Albertsen P.C., et al. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 1999, 54:567-572.
17. Weidner N., Carroll P.R., Flax J., Blumenfeld W., Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993, 143:401-409.
18. Jackson M.W., Roberts J.S., Heckford S.E., Ricciardelli C., Stahl J., Choong C., et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 2002, 62:854-859.
19. Duque J.L., Loughlin K.R., Adam R.M., Kantoff P., Mazzucchi E., Freeman M.R. Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics (Sao Paulo) 2006, 61:401-408.
20. Duque J.L., Loughlin K.R., Adam R.M., Kantoff P.W., Zurakowski D., Freeman M.R. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999, 54:523-527.
21. Bok R.A., Halabi S., Fei D.T., Rodriquez C.R., Hayes D.F., Vogelzang N.J., et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 2001, 61:2533-2536.
22. George D.J., Halabi S., Shepard T.F., Sanford B., Vogelzang N.J., Small E.J., et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res 2005, 11:1815-1820.
23. Isambert N, Freyer G, Zanetta S, Falandry C, Soussan Lazard K, Fumoleau P. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: preliminary results. J Clin Oncol: Official J Am Soc Clin Oncol 2008;26(Suppl. 15) [abstract 3599].
24. ClinicalTrials.gov registry. A multicenter, randomized, double blind study comparing the efficacy and safety of aflibercept versus placebo administered every 3 weeks in patients treated with docetaxel/prednisone for metastatic androgen-independent prostate cancer (VENICE) [identifier: NCT00519285]. <>; 2011 [accessed 31 August 2011]. http://clinicaltrials.gov/ct2/show/NCT00519285.
25. European Medicines Agency. AVASTIN: Summary of product characteristics. <>; 2011 [accessed 21 November 2011]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf.
26. European Medicines Agency. REVLIMID: summary of product characteristics. <>; 2012 [accessed 6 January 2012]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000717/WC500056018.pdf.
27. ClinicalTrials.gov registry. A phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in subjects with castrate-resistant prostate cancer (Mainsail) [identifier NCT00988208]. <>; 2011 [accessed 31 August 2011]. http://clinicaltrials.gov/ct2/show/NCT00988208.
28. Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF, Stadler WM, et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer: Survival results of CALBG 9041. J Clin Oncol: Official J Am Soc Clin Oncol 2010;28(Suppl. 18) [abstract LBA4511].
29. Celgene. Press release 22 November 2011. Celgene will discontinue phase III MAINSAIL(R) trial in castrate-resistant prostate cancer. <>; 2011 [accessed 5 December 2011]. http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1633148&highlight=.
30. Kelly W.K., Halabi S., Carducci M., George D., Mahoney J.F., Stadler W.M., et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol: Official J Am Soc Clin Oncol 2012, 30:1534-1540.
31. Olsson A., Bjork A., Vallon-Christersson J., Isaacs J.T., Leanderson T. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer 2010, 9:107.
32. ClinicalTrials.gov registry. A phase 3 randomized, double-blind, placebo-controlled study of tasquinimod in men with metastatic castrate resistant prostate cancer [identifier NCT01234311]. <>; 2012 [accessed 6 January 2012]. http://clinicaltrials.gov/ct2/show/NCT01234311.
33. Bagnato A., Rosano L. The endothelin axis in cancer. Int J Biochem Cell Biol 2008, 40:1443-1451.
34. ClinicalTrials.gov registry. Phase III study of docetaxel and atrasentan versus docetaxel and placebo for patients with advanced hormone refractory prostate cancer [identifier NCT00134056]. <>; 2011 [accessed 31 August 2011]. http://clinicaltrials.gov/ct2/show/NCT00134056.
35. Southwest Oncology Group. Press release April 21 2011. Addition of atrasentan to standard chemotherapy for advanced prostate cancer shows no benefit in phase III clinical trial. <>; 2011 [accessed 21 November 2011]. https://swog.org/Members/Download/BulletinBoard/Article200.pdf.
36. James N.D., Caty A., Payne H., Borre M., Zonnenberg B.A., Beuzeboc P., et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized phase II trial. BJU Int 2010, 106:966-973.
37. ClinicalTrials.gov registry. A phase III, randomised, double-blind, placebo-controlled study to assess the efficacy and safety of 10mg ZD4054 (zibotentan) in combination with docetaxel in comparison with docetaxel in patients with metastatic hormone-resistant prostate cancer (ENTHUSE M1C) [identifier NCT00617669]. <>; 2011 [accessed 31 August 2011]. http://clinicaltrials.gov/ct2/show/NCT00617669.
38. ClinicalTrials.gov registry. A phase III, randomised, placebo-controlled, double-blind study to assess the efficacy and safety of once-daily orally administered ZD4054 (zibotentan) 10mg in non-metastatic hormone-resistant prostate cancer patients (ENTHUSE M0) [Identifier NCT00626548]. <>; 2011 [accessed 1 September 2011]. http://clinicaltrials.gov/ct2/show/NCT00626548.
39. ClinicalTrials.gov registry. A phase III trial to test the efficacy of ZD4054 (zibotentan), an endothelin a receptor antagonist, versus placebo in patients with hormone resistant prostate cancer (HRPC) and bone metastasis who are pain free and mildly symptomatic (ENTHUSE M1) [identifier NCT00554229]. <>; 2011 [accessed 31 August 2011]. http://clinicaltrials.gov/ct2/show/NCT00554229.
40. Astrazeneca. Press release 27 September 2010. Results of zibotentan phase III trial in castration resistant prostate cancer. <>; 2011 [accessed 21 November 2011]. http://www.astrazeneca.com/Media/Press-releases/Article/Results-of-Zibotentan-Phase-III-trial-in-castration-resistant-pr.
41. Astrazeneca. Press release 7 February 2011. AstraZeneca halts phase III trial of zibotentan in non-metastatic castrate resistant prostate cancer. <>; 2011 [accessed 21 November 2011]. http://www.astrazeneca.com/Media/Press-releases/Article/0022011AstraZeneca-halts-phase-III-trial-of-ZIBOTENTAN.
42. Park S.I., Zhang J., Phillips K.A., Araujo J.C., Najjar A.M., Volgin A.Y., et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008, 68:3323-3333.
43. Tatarov O., Mitchell T.J., Seywright M., Leung H.Y., Brunton V.G., Edwards J. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 2009, 15:3540-3549.
44. Koreckij T., Nguyen H., Brown L.G., Yu E.Y., Vessella R.L., Corey E. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer 2009, 101:263-268.
45. Araujo J.C., Mathew P., Armstrong A.J., Braud E.L., Posadas E., Lonberg M., et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer 2012, 118:63-71.
46. ClinicalTrials.gov registry. A randomized double-blind phase 3 trial comparing docetaxel combined with dasatinib to docetaxel combined with placebo in castration-resistant prostate cancer [identifier NCT00744497]. <>; 2011 [accessed 23 July 2011]. http://clinicaltrials.gov/ct2/show/NCT00744497.
47. You W.K., McDonald D.M. The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep 2008, 41:833-839.
48. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
49. Hussain M, Smith MR, Sweeney C, Corn PG, Elfiky A, Gordon MS, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. J Clin Oncol: Official J Am Soc Clin Oncol 2011;29(Suppl. 15) [abstract 4516].
50. ClinicalTrials.gov registry. A phase II trial of cabozantinib (XL184) in patients with castrate-resistant prostate cancer metastatic to bone [identifier NCT01428219]. <>; 2011 [accessed 22 November 2011]. http://clinicaltrials.gov/ct2/show/NCT01428219.
51. Seruga B., Ocana A., Tannock I.F. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2011, 8:12-23.
52. Loriot Y., Massard C., Gross-Goupil M., Di Palma M., Escudier B., Bossi A., et al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer 2010, 46:1770-1772.
53. de Bono J.S., Oudard S., Ozguroglu M., Hansen S., Machiels J.P., Kocak I., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
54. ClinicalTrials.gov registry. Cabazitaxel versus docetaxel both with prednisone in patients with metastatic castration resistant prostate cancer (FIRSTANA) [indentifer NCT01308567]. <>; 2012 [accessed 6 January 2012]. http://clinicaltrials.gov/ct2/show/NCT01308567.
55. ClinicalTrials.gov registry. Randomized, open label multi-center study comparing cabazitaxel at 20mg/m2 and at 25mg/m2 every 3 weeks in combination with prednisone for the treatment of metastatic castration resistant prostate cancer previously treated with a docetaxel-containing regimen [identifier NCT01308580]. <>; 2011 [accessed 5 December 2011]. http://clinicaltrials.gov/ct2/show/NCT01308580.
56. Donkena K.V., Yuan H., Young C.Y. Recent advances in understanding hormonal therapy resistant prostate cancer. Curr Cancer Drug Targets 2010, 10:402-410.
57. Oesterling J.E., Hauzeur C.G., Farrow G.M. Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J Urol 1992, 147:804-807.
58. Shah S., Ryan C. Abiraterone acetate for castration resistant prostate cancer. Expert Opin Investig Drugs 2010, 19:563-570.
59. de Bono JS, Logothetis CJ, Fizazi K, North S, Chu L, Chi KN, et al. Abiraterone acetate plus low dose prednisone improves overall survival in patients with metastatic castration-resistant prostate cancer who have progressed after docetaxel-based chemotherapy: results of COU-AA-301, a randomized double-blind placebo-controlled phase III study. Ann Oncol 2010;21(Suppl. 8):viii3 [abstract LBA5].
60. de Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005.
61. Fizazi K, Scher HI, Molina A, Logothetis CJ, Jones RJ, Staffurth JN, et al. Final overall survival (OS) analysis of COU-AA-301, a phase 3 study of abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) pretreated with docetaxel. Eur J Cancer 2011;47(Suppl. 1):S483-4 [abstract 7000].
62. Goodman OB, Chi KN, Molina A, Logothetis C, Jones RJ, Staffurth J, et al. Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol: Official J Am Soc Clin Oncol 2012;30(Suppl. 15) [abstract 4558].
63. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis C, De Souza PL, on behalf of the COU-AA-302 Investigators. Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol: Official J Am Soc Clin Oncol 2012;30(Suppl. 18) [abstract LBA4518].
64. Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787-790.
65. Scher H.I., Beer T.M., Higano C.S., Anand A., Taplin M.E., Efstathiou E., et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010, 375:1437-1446.
66. ClinicalTrials.gov registry. A multinational phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of oral MDV3100 in chemotherapy-naive patients with progressive metastatic prostate cancer who have failed androgen deprivation therapy (PREVAIL) [identifier NCT01212991]. <>; 2011 [accessed 26 August 2011]. http://clinicaltrials.gov/ct2/show/study/NCT01212991.
67. Medivation. Press release, 3 November 2011. Medivation and Astellas announce positive survival data from interim analysis of phase 3 AFFIRM trial of MDV3100 in men with advanced prostate cancer. <>; 2012 [accessed 5 January 2012]. http://investors.medivation.com/releasedetail.cfm?ReleaseID=620500.
68. de Bono JS, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, for the AFFIRM Investigators. Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor. J Clin Oncol: Official J Am Soc Clin Oncol 2012;30(Suppl. 15) [abstract 4519].
69. Higano C.S., Schellhammer P.F., Small E.J., Burch P.A., Nemunaitis J., Yuh L., et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115:3670-3679.
70. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
71. Small E.J., Schellhammer P.F., Higano C.S., Redfern C.H., Nemunaitis J.J., Valone F.H., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol: Official J Am Soc Clin Oncol 2006, 24:3089-3094.
72. Kantoff P.W., Schuetz T.J., Blumenstein B.A., Glode L.M., Bilhartz D.L., Wyand M., et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol: Official J Am Soc Clin Oncol 2010, 28:1099-1105.
73. ClinicalTrials.gov registry. A randomized, double-blind, phase 3 efficacy trial of PROSTVAC±GM-CSF in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer identifier NCT01322490]. <>; 2011 [accessed 26 August 2011]. http://clinicaltrials.gov/ct2/show/NCT01322490.
74. Beer T.M., Ryan C.W. The hazards of intermediate endpoints. Cancer 2007, 110:1877-1879.
75. Tarhini A.A., Iqbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther 2010, 3:15-25.
76. Tollefson MK, Karnes RJ, Thompson RH, Granberg CF, Hillman DW, Breau RH, et al. A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer. In: Presentation at American Society of Clinical Oncology Genitourinary Cancers Symposium (abstract 168). <>; 2010 [accessed 6 January 2012]. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID=30897.
77. ClinicalTrials.gov registry. Randomized, double-blind, phase 3 trial to compare the efficacy of ipilimumab vs. placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naïve castration resistant prostate cancer [identifier NCT01057810]. <>; 2011 [accessed 26 August 2011]. http://clinicaltrials.gov/ct2/show/NCT01057810.
78. ClinicalTrials.gov registry. A randomized, double-blind, phase 3 trial comparing ipilimumab vs. placebo following radiotherapy in subjects with castration resistant prostate cancer that have received prior treatment with docetaxel [identifier NCT00861614]. <>; 2011 [accessed 26 August 2011]. http://clinicaltrials.gov/ct2/show/NCT00861614.
79. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27:165-176.
80. Roodman G.D., Dougall W.C. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 2008, 34:92-101.
81. Keller E.T., Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 2004, 91:718-729.
82. Lage M.J., Barber B.L., Harrison D.J., Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008, 14:317-322.
83. DePuy V., Anstrom K.J., Castel L.D., Schulman K.A., Weinfurt K.P., Saad F. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 2007, 15:869-876.
84. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94:1458-1468.
85. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 96:879-882.
86. Diel I.J., Bergner R., Grotz K.A. Adverse effects of bisphosphonates: current issues. J Support Oncol 2007, 5:475-482.
87. European Medicines Agency. Zometa (zoledronic acid): summary of product characteristics. <>; 2011 [accessed 21 November 2011]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000336/WC500051730.pdf.
88. Smith M.R., Egerdie B., Hernandez Toriz N., Feldman R., Tammela T.L., Saad F., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009, 361:745-755.
89. European Medicines Agency. XGEVA: summary of product characteristics. <>; 2011 [accessed 23 August 2011]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002173/WC500110381.pdf.
90. US Food and Drug Administration: Drugs@FDA database. XGEVA (denosumab): highlights of prescribing information. <>; 2011 [accessed 10 November 2011]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125320s007lbl.pdf.
91. Fizazi K., Carducci M., Smith M., Damião R., Brown J., Karsh L., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377:813-822.
92. Chen G., Sircar K., Aprikian A., Potti A., Goltzman D., Rabbani S.A. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006, 107:289-298.
93. Sabbota A.L., Kim H.R., Zhe X., Fridman R., Bonfil R.D., Cher M.L. Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. Cancer Res 2010, 70:5558-5566.
94. Smith M.R., Saad F., Coleman R., Shore N., Fizazi K., Tombal B., et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012, 379:39-46.
95. Chiacchio S., Mazzarri S., Lorenzoni A., Nyakale N., Boni G., Borso E., et al. Radionuclide therapy and integrated protocols for bone metastases. Q J Nucl Med Mol Imaging 2011, 55:431-447.
96. Parker C, Heinrich D, O'Sullivan JM, Fossa S, Chodacki A, Demkow T, et al. Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA). Eur J Cancer 2011;47(Suppl. 2):3 [abstract 1LBA].
97. Algeta. Press release, 23 August 2011. FDA grants fast track designation to alpharadin for the treatment of castration-resistant prostate cancer patients with bone metastases. <>; 2012 [accessed 4 January 2012]. http://hugin.info/134655/R/1540232/470883.pdf.
98. Parker C, Nilsson S, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol: Official J Am Soc Clin Oncol 2012;30(Suppl. 18) [abstract LBA4512].
99. Azria D, Massard C, Tosi D, Houede N, Joly F, Gravis G, et al. An ambispective observational study in the safety and efficacy of abiraterone acetate in the French temporary authorizations for use (ATU): Predictive parameters of response. J Clin Oncol: Official J Am Soc Clin Oncol 2012;30(Suppl. 5) [abstract 149].
100. Loriot Y, Massard C, Albiges L, Di Palma M, Blanchard P, Bossi A, et al. Personalizing treatment in patients with castrate-resistant prostate cancer: a study of predictive factors for secondary endocrine therapies activity. J Clin Oncol: Official J Am Soc Clin Oncol 2012;30(Suppl. 5) [abstract 213].
101. Dearnaley D.P., Mason M.D., Parmar M.K., Sanders K., Sydes M.R. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 2009, 10:872-876.
102. Brown J.E., Cook R.J., Major P., Lipton A., Saad F., Smith M., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005, 97:59-69.
103. Lipton A., Cook R., Saad F., Major P., Garnero P., Terpos E., et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008, 113:193-201.
104. Libener R, Montefiore F, Bonini F, Ruggero L, Maffezzini M, Puntoni M, et al. Sensitivity and specificity of osteopontin (OPN) versus prostate-specific antigen (PSA) in prostate carcinoma (PCa): A case- control study. ASCO Meeting Abstracts 2009;27(Suppl. 15) [abstract e16082].
105. Prager AJ, Peng CR, Lita E, McNally D, Kaushal A, Sproull M, et al. Urinary osteopontin as a marker for localized and metastatic prostate cancer. J Clin Oncol: Official J Am Soc Clin Oncol 2011;29(Suppl.) [abstract e15147].
106. Ide H., Hatake K., Terado Y., Tsukino H., Okegawa T., Nutahara K., et al. Serum level of macrophage colony-stimulating factor is increased in prostate cancer patients with bone metastasis. Hum Cell 2008, 21:1-6.
107. Shaffer D.R., Leversha M.A., Danila D.C., Lin O., Gonzalez-Espinoza R., Gu B., et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007, 13:2023-2029.
108. Chi K.N., Hotte S.J., Yu E.Y., Tu D., Eigl B.J., Tannock I., et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol: Official J Am Soc Clin Oncol 2010, 28:4247-4254.
109. ClinicalTrials.gov registry. A randomized phase 3 study comparing standard first-line docetaxel/prednisone to docetaxel/prednisone in combination with custirsen (OGX-011) in men with metastatic castrate resistant prostate cancer [identifier NCT01188187]. <>; 2011 [accessed 25 August 2011]. http://clinicaltrials.gov/ct2/show/NCT01188187.
110. ClinicalTrials.gov registry. A randomized, placebo-controlled, double-blind, phase 3 study evaluating the benefit of adding custirsen to docetaxel retreatment as second-line therapy in men with castrate resistance prostate cancer [identifier NCT01083615]. <>; 2011 [accessed 25 August 2011]. http://clinicaltrials.gov/ct2/show/NCT01083615.
111. Pili R, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, et al. A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naïve patients with metastatic castrate-resistant prostate cancer (CRPC). J Clin Oncol: Official J Am Soc Clin Oncol 2010;28(Suppl. 15) [abstract 4510].
112. Picus J., Halabi S., Kelly W.K., Vogelzang N.J., Whang Y.E., Kaplan E.B., et al. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer 2011, 117:526-533.
113. Carducci M.A., Padley R.J., Breul J., Vogelzang N.J., Zonnenberg B.A., Daliani D.D., et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol: Official J Am Soc Clin Oncol 2003, 21:679-689.
114. Scher H.I., Jia X., Chi K., de Wit R., Berry W.R., Albers P., et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol: Official J Am Soc Clin Oncol 2011, 29:2191-2198.
115. Petrylak DP, Resto-Garces K, Tibyan M, Mohile SG. A phase I open-label study using lenalidomide and docetaxel in castration-resistant prostate cancer. J Clin Oncol: Official J Am Soc Clin Oncol 2009;27(Suppl. 15) [abstract 5156].
116. Oh W.K., Halabi S., Kelly W.K., Werner C., Godley P.A., Vogelzang N.J., et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: cancer and leukemia Group B 99813. Cancer 2003, 98:2592-2598.
117. ClinicalTrials.gov registry. Phase II study of carboplatin plus docetaxel (taxotere) in patients with anaplastic prostate carcinoma [identifier NCT00514540]. <>; 2011 [accessed 25 August 2011]. http://clinicaltrials.gov/ct2/show/NCT00514540.
118. Sternberg C.N., Petrylak D.P., Sartor O., Witjes J.A., Demkow T., Ferrero J.M., et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol: Official J Am Soc Clin Oncol 2009, 27:5431-5438.
119. Dreicer R, Agus DB, MacVicar GR, Wang J, MacLean D, Stadler WM. Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: a phase I/II, open-label study. J Clin Oncol: Official J Am Soc Clin Oncol 2010;28(Suppl. 15) [abstract 3084].
120. ClinicalTrials.gov registry. Study comparing orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer [identifier NCT01193244]. <>; 2011 [accessed 26 August 2011]. http://clinicaltrials.gov/ct2/show/NCT01193244.
121. ClinicalTrials.gov registry. Study comparing orteronel plus prednisone in patients with metastatic castration-resistant prostate cancer [identifier NCT01193257]. <>; 2011 [accessed 26 August 2011]. http://clinicaltrials.gov/ct2/show/NCT01193257.
122. Higano C.S., Corman J.M., Smith D.C., Centeno A.S., Steidle C.P., Gittleman M., et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008, 113:975-984.
123. ClinicalTrials.gov registry. A phase III randomized, open-label study of CG1940 and CG8711 versus docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer who are chemotherapy-naïve [identifier NCT00089856]. <>; 2011 [accessed 26 August 2011]. http://clinicaltrials.gov/ct2/show/NCT00089856.
124. Smith MR, Saad F, Shore ND, Oudard S, Miller K, Tombal B, et al. Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastastic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics. J. Clin Oncol 2012;30 [abstract 6].